RxDoctor Payments DataLook up a doctor →

Jennifer Soung, MD

Dermatology · Santa Ana, CANPI 1346408226

Payments from drug & device makers

$10,253,731in general payments, 2019–2025

Across 4,217 payments — averaging $2431.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2.2M
  • Eli Lilly$1.5M
  • Janssen Research & Development, LLC$1.3M
  • AbbVie$826K
  • UCB SA$714K
  • Lilly USA, LLC$543K
  • plus $3.2M from 36 others
$42,847in research payments, 2019–2025

Across 30 payments — averaging $1428.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$20K
  • Eli Lilly$17K
  • Novartis$4K
  • Amgen$2K
  • Eli Lilly Export S.A. Puerto Rico Branch$750

What the payments were for

  • Consulting fees$819,60330%
  • Speaking & faculty fees$1,677,76261%
  • Travel & lodging$200,7027%
  • Food & beverage$72,2083%
  • Education$3500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,253,731 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$56,196
Medicare patients
140
Services billed
505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab49$424,264
Skyrizi PenRisankizumab-Rzaa11$217,448
TremfyaGuselkumab13$177,633
Dupixent SyringeDupilumab24$86,371
Dupixent PenDupilumab13$48,691
Fluocinonide58$2,166
Cyclosporine ModifiedCyclosporine, Modified23$1,587
Fluocinolone Acetonide21$1,126
Fluorouracil13$727
Clindamycin Phosphate33$617
Triamcinolone Acetonide57$524
Hydrocortisone31$477
Clobetasol Propionate16$468
Betamethasone Dipropionate12$437
Minoxidil57$387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$218,677$177,63313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,875 dermatology providers in California.

Other dermatology in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →